Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.

In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.

Recent Videos
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content
Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.

ZEN-3694 Earns FDA Fast Track Designation in Metastatic NUT Carcinoma

Russ Conroy
July 16th 2025
Article

Investigators are evaluating ZEN-3694 in combination with abemaciclib or cisplatin/etoposide across 2 clinical trials in NUT carcinoma.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma

Russ Conroy
July 10th 2025
Article

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.

YL201 Demonstrates Tolerability, Early Efficacy in Advanced Solid Tumors

Roman Fabbricatore
July 7th 2025
Article

Among 287 patients across multiple solid tumor indications, YL201 had an objective response rate of 40.8%, with a disease control rate of 83.6%.

Male Cancer Survivors in Physically Demanding Jobs Need More Support

Male Cancer Survivors in Physically Demanding Jobs Need More Support

Ariana Pelosci
July 5th 2025
Article

Findings from a WeCanWork study showed that men who work laborious jobs need additional support during and after cancer treatment.